GlassScriptPhysician profile
Bechara Barrak
NPI 1912928177
$30,014.95
in general payments reported to CMS, 2019-2025
71 companies · $3,358 in 2025
The $3,358 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,247 · 2020: $3,119 · 2021: $5,231 · 2022: $4,209 · 2023: $3,964 · 2024: $3,888 · 2025: $3,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,030.19 |
| Education | $179.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,357.75 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $2,977.68 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $2,552.01 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $2,121.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,801.03 | 2019-2025 | Spravato |
| Pfizer INC. | $1,325.52 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,174.92 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Lilly USA, LLC | $1,113.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $1,069.71 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $969.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $968.56 | 2019-2025 | |
| Amgen INC. | $937.74 | 2019-2025 | Repatha, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $853.01 | 2019-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $675.88 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $483.80 | 2019-2022 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bechara Barrak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.